Older patients benefit from XELOX after surgery

Update from 2010 GI Cancers Symposium Colon cancer patients over 70 actually had a greater reduction in disease-free survival than did younger ones with a new regimen of Xeloda® and oxaliplatin compared to older IV 5-FU treatments according to a new analysis reported at the GI Cancers Symposium in Orlando. With the bolus IV 5-FU and…  Read More

Colorectal Cancer News in Brief: November 7

Briefly Patients with diabetes aren’t any more likely to develop neuropathy in hands and feet when treated with oxaliplatin. Learn more about  current colorectal cancer prevention and treatment at a Memorial Sloan Kettering CancerSmart workshop on November 12.  NIH has a downloaded booklet on palliative care, and Oncology on Canvas is looking for artwork from cancer…  Read More

XELOX Beats 5-FU with Fewer Recurrences

A combination of Xeloda and Eloxatin (XELOX) was better than standard 5-FU and leucovorin chemotherapy in reducing recurrences of stage III colon cancer after surgery.  Significantly more patients receiving XELOX were alive without cancer three years after treatment began. Roche announced results of a Phase III clinical trial that compared XELOX chemotherapy to bolus 5-FU and…  Read More